EBR Systems (ASX:EBR) has cleared a key CMS gate, with a National Coverage Determination for WiSE now tracking to a March 2027 Medicare decision.
Healthcare Stocks
Island Pharmaceuticals (ASX:ILA) starts GMP manufacturing of Galidesivir with PI Health Sciences, the last big step before a pivotal Marburg FDA submission.
Propel Funeral Partners (ASX:PFP) unveils three NZ acquisitions worth up to A$9.1m and FY26 guidance showing flat EBITDA against FY25.
Opthea (ASX:OPT) returns to trading with A$31.2m, a LAM rare disease program and a proposed name change to Ceryvyn Therapeutics.
Imagion Biosystems (ASX:IBX) wins FDA IND clearance for MagSense HER2 Phase 1b/2 trial, with patient recruitment now targeted for Q3 2026.
4DMedical (ASX:4DX) launches the CLEAR study with Mass General Brigham to push CT VQ into the US$2.5B pulmonary embolism imaging market.
ReNerve (ASX:RNV) signs exclusive distribution deal with Swedish Trading Company covering Hong Kong, Macau and the Greater Bay Area’s 88 million population.
Austco Healthcare (ASX:AHC) guides to FY26 NPAT growth of 52% to 58% and a 180-hospital US Pulse Mobile rollout in 2026.
Pro Medicus (ASX:PME) has signed a 7-year, A$16m contract with TidalHealth covering the full Visage 7 stack plus cardiology, delivered in the cloud.
Acrux (ASX:ACR) signs A$5.4m Lenzetto licensing amendment with Gedeon Richter, bringing the Estradiol spray to Australia’s short MHT market.
